Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of kidney failure, cardiovascular events, and death in patients with chronic kidney disease and/or heart failure, regardless of diabetes status. This evidence concerns the gene SLC5A2 and chronic kidney disease.